Literature DB >> 2945858

Cooperativity between B lymphocyte membrane molecules: independent ligand occupancy and cross-linking of antigen receptors and Fc gamma receptors down-regulates B lymphocyte function.

F Uher, H B Dickler.   

Abstract

IgG antibody-antigen complexes bound to B lymphocyte Fc gamma receptor (Fc gamma R) but not surface immunoglobulin inhibit the antibody-forming cell response but not proliferation of these cells in response to F(ab')2 anti-mu and lymphokines. The role of B lymphocyte antigen receptors in B lymphocyte Fc gamma R-mediated inhibition was evaluated. With the use of several different antigen receptor-dependent plaque-forming cell (PFC) responses, it was found that inhibition occurred irrespective of the type of stimulatory signal used, or whether antigen receptors were bound by antibody or occupied by nominal antigen. The degree of inhibition appeared to be directly related to the extent of antigen receptor cross-linking. Maximal inhibition only occurred if both antigen receptors and Fc gamma R were occupied by their respective ligands simultaneously during the early hours of activation. In contrast, antigen receptor-independent PFC responses to the mitogen lipopolysaccharide (LPS) were not inhibited by complexes. However, the antigen-independent TNP-specific PFC response to LPS was inhibited by the combination of IgG antibody-antigen complexes and the hapten, but by neither alone. These results suggest that a down-regulatory signal is generated by functional cooperation between Fc gamma R and antigen receptors. Generation of this inhibiting signal could be mediated by the previously described physical interaction between these two receptors, and interactions between membrane receptors may be a general mechanism utilized by lymphocytes for the integration of multiple signals.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2945858

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  5 in total

Review 1.  Intravenous immunoglobulins (IVIg) in the treatment of autoimmune diseases.

Authors:  S V Kaveri; G Dietrich; V Hurez; M D Kazatchkine
Journal:  Clin Exp Immunol       Date:  1991-11       Impact factor: 4.330

2.  Inhibition of immunoglobulin E synthesis through Fc gammaRII (CD32) by a mechanism independent of B-cell receptor co-cross-linking.

Authors:  Jutta Horejs-Hoeck; Andrea Hren; Geert C Mudde; Maximilian Woisetschläger
Journal:  Immunology       Date:  2005-07       Impact factor: 7.397

3.  The potential of immunization with synthetic peptides to overcome the immunosuppressive effect of maternal anti-measles virus antibodies in young mice.

Authors:  O E Obeid; M W Steward
Journal:  Immunology       Date:  1994-05       Impact factor: 7.397

4.  Measles virus nucleocapsid protein binds to FcgammaRII and inhibits human B cell antibody production.

Authors:  K Ravanel; C Castelle; T Defrance; T F Wild; D Charron; V Lotteau; C Rabourdin-Combe
Journal:  J Exp Med       Date:  1997-07-21       Impact factor: 14.307

Review 5.  Update on Intravenous Immunoglobulin in Neurology: Modulating Neuro-autoimmunity, Evolving Factors on Efficacy and Dosing and Challenges on Stopping Chronic IVIg Therapy.

Authors:  Marinos C Dalakas
Journal:  Neurotherapeutics       Date:  2021-11-11       Impact factor: 7.620

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.